- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Patient with metastatic castration-sensitive prostate cancer (CSPC) treated with androgen deprivation therapy (ADT) and docetaxel experienced bet...
More than a decade after its founding, Agios Pharmaceuticals has its first FDA green light. With the approval for Pyrukynd to treat hemolytic ane...
While the survival rate for children with acute lymphoblastic leukemia (ALL)—the most common cancer in children—is more than 80%, survival among ...
Treatment with aspirin did not result in an invasive disease-free survival (iDFS) benefit for patients with stage II or III HER2-negative breast ...
The FDA has granted fast track designation to pidnarulex (CX-5461) for the treatment of ovarian and breast cancer with BRCA1/2, PALB2, or other h...
Patients with prostate cancer are at an increased risk of developing significant depression investigators highlighting a need to conduct screenin...
The FDA has granted a breakthrough device designation to the TriNetra-Prostate blood test for use in the detection of early-stage prostate cancer...
The FDA has accepted a new drug application (NDA) for the use of adagrasib (MRTX849) in the treatment of patients with non–small cell lung cancer...
The FDA has granted an orphan drug designation to the off-the-shelf natural killer (NK) cell therapy CYNK-101 as a potential treatment for patien...
Treatment with sotorasib (Lumakras) resulted in clinically meaningful responses in a population of patients with heavily pretreated KRAS G12C...
